Research
Hormonal
Phentermine/topiramate combination therapy produces significant weight loss (up to 8.6% vs placebo) and improves metabolic markers, but is contraindicated in patients with unstable cardiovascular disease.
This combination medication can help you lose weight and improve your metabolic health. It works by suppressing appetite and increasing energy expenditure. Because it can affect heart rate and blood pressure, it is not suitable for everyone, especially those with heart conditions. You must start with a low dose and increase it slowly to minimize side effects like tingling or dry mouth.
StrongSupportsHIGH confidence
Qsymia®... CONQUER study... maximum treatment dose 15/92 mg... 8.6% weight loss compared to placebo... contraindicated in patients with recent or unstable cardiovascular disease
Why this rating
Large randomized controlled trials (EQUIP, CONQUER) cited.
Source
Recent Advances in Anti-Obesity Drugs
Jang Won Son · Journal of Korean Diabetes · 2022
DOI 10.4093/jkd.2022.23.2.113
narrative_reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant weight loss (5-15%) and improve cardiometabolic risk factors in adults with obesity, with efficacy increasing with higher doses.Strong
- Naltrexone/bupropion combination therapy produces moderate weight loss (up to 6.1% vs placebo) and improves metabolic markers, but carries risks of seizures and psychiatric side effects.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →